

LIBERIA

Support for DTP-HepB-Hib Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Liberia						
2. Vaccine grant number:	07-LBR-08b-Y, 1115-LBR-04A-X, 16-LBR-04a-X, 1720-LBR-04a-X, 18-LBR-04g-Y, 1820-LBR-04c-X						
3. Date of Decision Letter:	30-Sep-2019						
4. Date of the Partnership Framework Agreement:	19 August 2013						
5. Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine						
6. Vaccine type:	DTP-HepB-Hib						
7. Requested product presentation and formulation of vaccine:	Penta, 10 doses per vial, LIQUID						
8. Programme Duration:¹	2008-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2008-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	11,328,609	-	-	-	-	-	11,328,609
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2007	07-LBR-08b-Y	100,000				
	Disbursement						
	Disbursement date		Amount (US\$)				
	27 July, 2007		100,000				
11. Product switch grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2018	18-LBR-04g-Y	35,680				
	Disbursement						
	Disbursement date		Amount (US\$)				
	31 August, 2018		35,680				
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2008-2019	2020	2021
Number of vaccine doses		-	-
Annual Amounts (US\$)	11,328,609	-	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	-	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	-	-	-	-	-
Total co-financing payments (US\$) (including freight)	-	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Country shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
---	------------------------------------

18. Financial clarifications:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30-Sep-2019